Definium Therapeutics, Inc. (DFTX)
30.14
-1.94
(-6.05%)
USD |
NASDAQ |
Nov 16, 16:00
30.14
0.00 (0.00%)
After-Hours: 20:00
Definium Therapeutics Enterprise Value : 3.381B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 3.381B |
| November 12, 2026 | 3.507B |
| November 11, 2026 | 3.708B |
| November 10, 2026 | 3.732B |
| November 09, 2026 | 3.834B |
| November 06, 2026 | 3.544B |
| November 05, 2026 | 3.146B |
| November 04, 2026 | 3.466B |
| November 03, 2026 | 3.563B |
| November 02, 2026 | 3.435B |
| October 30, 2026 | 3.963B |
| October 29, 2026 | 4.186B |
| October 28, 2026 | 4.205B |
| October 27, 2026 | 4.066B |
| October 26, 2026 | 3.874B |
| October 23, 2026 | 3.873B |
| October 22, 2026 | 3.918B |
| October 21, 2026 | 3.848B |
| October 20, 2026 | 3.793B |
| October 19, 2026 | 3.503B |
| October 16, 2026 | 3.384B |
| October 15, 2026 | 3.680B |
| October 14, 2026 | 3.677B |
| October 13, 2026 | 3.696B |
| October 12, 2026 | 3.808B |
| Date | Value |
|---|---|
| October 09, 2026 | 4.041B |
| October 08, 2026 | 3.669B |
| October 07, 2026 | 3.793B |
| October 06, 2026 | 3.866B |
| October 05, 2026 | 3.949B |
| October 02, 2026 | 4.109B |
| October 01, 2026 | 4.137B |
| September 30, 2026 | 4.200B |
| September 29, 2026 | 4.087B |
| September 28, 2026 | 4.114B |
| September 25, 2026 | 3.813B |
| September 24, 2026 | 3.888B |
| September 23, 2026 | 4.011B |
| September 22, 2026 | 4.370B |
| September 21, 2026 | 4.230B |
| September 18, 2026 | 4.167B |
| September 17, 2026 | 4.150B |
| September 16, 2026 | 4.038B |
| September 15, 2026 | 3.900B |
| September 14, 2026 | 4.361B |
| September 11, 2026 | 4.178B |
| September 10, 2026 | 4.022B |
| September 09, 2026 | 4.057B |
| September 08, 2026 | 4.089B |
| September 04, 2026 | 4.071B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Enliven Therapeutics, Inc. | 2.707B |
| Cocrystal Pharma, Inc. | 12.61M |
| CNBX Pharmaceuticals, Inc. | 1.305M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | -104.09M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -50.96M |
| Total Expenses (Quarterly) | 50.96M |
| EPS Diluted (Quarterly) | -0.3749 |
| Earnings Yield | -10.06% |
| Normalized Earnings Yield | -7.910 |